

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-10 (canceled)

Claim 11 (new): A method of treating a mutated-RET kinase associated disease comprising administering an effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide or a pharmaceutically acceptable salt thereof wherein the mutated-RET kinase associated diseases comprises thyroid cancers, pheochromocytoma, mucosal neuromas, hyperparathyroidism, parathyroid hyperplasia, Hirschsprungs disease or Cutaneous Lichen amyloidosis.

Claim 12 (new): The method according to claim 11 wherein the thyroid cancer is selected from medullary thyroid carcinomas and papillary thyroid carcinomas.

Claim 13 (new): The method according to claim 11 wherein the medullary thyroid carcinomas are the hereditary multiple endocrine neoplasias type 2.

Claim 14 (new): The method according to claim 11 wherein the hereditary multiple endocrine neoplasias type 2 are MEN2A, MEN2B or FMTC.

Claim 15 (new): The method according to claim 11, wherein the effective amount is a daily dose of 10 to 1000 mg of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of formula I is administered to an adult.

Claim 16 (new): The method according to claim 15, wherein the monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide is administered.

Claim 17 (new): The method according to claim 11, wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide is in mesylate salt form and in the beta crystal form thereof.